Biotechnology News and Research

RSS

J. Craig Venter Institute offers new Affymetrix array for faster identification of E. coli and shigella

Affymetrix, Inc. and the National Institute of Allergy and Infectious Diseases (NIAID)-supported Pathogen Functional Genomics Resource Center (PFGRC) at the J. Craig Venter Institute (JCVI) today announced the launch of the Affymetrix FDA-ECSG custom microarray for identifying and discriminating between different strains of E. coli and Shigella.

6 Aug 2009

Innexus Biotechnology announces business development initiative on lead preclinical candidate

InNexus Biotechnology Inc. announced today that the Company will embark on a business development initiative for DXL625™ (CD20), the Company’s lead preclinical candidate for the prospective treatment of Non-Hodgkin’s Lymphoma and/or Chronic Lymphocytic Leukemia.

6 Aug 2009

Genzyme’s Mozobil approved in Europe

Genzyme Corporation announced today that the European Commission has granted marketing authorization for Mozobil ® (plerixafor injection), providing a significant new option for patients with the blood cancers lymphoma and multiple myeloma who require an autologous stem cell transplant.

6 Aug 2009

Appeals court affirms invalidation of Yasmin patent

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Court of Appeals for the Federal Circuit has affirmed a ruling by the U.S. District Court for the District of New Jersey finding Bayer Schering's U.S. Patent No. 6,787,531 invalid. The patent is listed in the Orange Book for Bayer's oral contraception Yasmin®.

5 Aug 2009

Baxter completes production of batches of CELVAPAN A/H1N1 pandemic vaccine

Baxter International Inc. (NYSE: BAX) today announced that it completed production of its first commercial batches of CELVAPAN A/H1N1 pandemic vaccine in late July and is discussing plans for distribution with national health authorities, subject to obtaining appropriate authorizations. CELVAPAN, the brand name for the company’s A/H1N1 pandemic influenza vaccine, is made using Baxter’s proprietary Vero cell culture technology.

From Baxter International Inc. 5 Aug 2009

Aptamers offer unique therapeutic advantages

A novel class of drugs composed of single strands of DNA or RNA, called aptamers, can bind protein targets with a high strength and specificity and are currently in clinical development as treatments for a broad range of common diseases, as described in a comprehensive review article published online ahead of print in Oligonucleotides.

5 Aug 2009

Aspermont and AusBiotech announce significant joint venture

Aspermont Limited today announced that the company will launch a regionally focused life sciences news service in conjunction with the national biotechnology industry association, AusBiotech.

5 Aug 2009

Cancer Therapy & Research Center (CTRC) retains status as NCI-designated cancer center

The National Cancer Institute, the nation’s top cancer research organization, has renewed the Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio as one of its NCI-designated Cancer Centers for three years. The distinction comes with $5.4 million in new federal funding through 2012 to sustain and grow the cancer center’s rapidly expanding research programs, now consisting of 140 scientists at work on a multitude of cancer projects.

4 Aug 2009

Compound from coral offers hope fpr neuropathic pain

A compound initially isolated from a soft coral (Capnella imbricata) collected at Green Island off Taiwan, could lead scientists to develop a new set of treatments for neuropathic pain - chronic pain that sometimes follows damage to the nervous system.

4 Aug 2009

Clinical trial to test gene therapy for Alzheimer’s disease

Researchers at the Shiley-Marcos Alzheimer's Disease Research Center at the University of California San Diego are about to launch a Phase 2 clinical trial to test a gene therapy treatment for Alzheimer’s disease (AD) called CERE-110.

4 Aug 2009

Lobbyists play ball, flex muscles on health care reform

The Associated Press reports on lobbying around biotechnology legislation. A letter urging the protection of biotech drug makers from generics from "the private National Health Council, sent to House leaders drafting health overhaul legislation, said the plea was on behalf of 'the more than 133 million Americans living with chronic diseases and disabilities and their family caregivers.'

4 Aug 2009

Viral RNA linked to human immune response

In its fight against an intruding virus, an enzyme in our immune system may sense certain types of viral RNA pairs, according to scientists.

4 Aug 2009

Carbon nanosensor sniffs out kidney disease

A carbon nanosensor “electronic nose” - first developed by Technion-Israel Institute of Technology researchers to detect cancer from breath samples - has been modified to identify chronic renal failure (CRF).

4 Aug 2009

New bio-hybrid materials could be used as sensors, catalysts, drug-delivery systems, more

Bacteria play a role in myriad industrial processes from fermentation to cleaning up environmental pollution. But floating freely in solution, the microbial cells constantly multiply, generating biomass that must be removed periodically, causing downtime. Additionally, the microorganisms cannot be localized to a specific region of interest.

3 Aug 2009

Scientists discover original source of malignant malaria

Researchers have identified what they believe is the original source of malignant malaria: a parasite found in chimpanzees in equatorial Africa.

3 Aug 2009

Tiny device to 'sniff out' disease, heart attacks, poison and environmental pollution

Like the sensitive seismographs that can pick up tremors of impending earthquakes long before they strike, a similar invention from Tel Aviv University researchers may change the face of molecular biology.

3 Aug 2009

Opportunities and risks posed by synthetic biology

The new research field of synthetic biology will, in the medium term, open up a great deal of potential for combining novel genetic methods with engineering principles. This will facilitate the development, not only of new vaccines and medicines, but also of fuels and new materials.

3 Aug 2009

Dynamic, 3D pattern formation within protein-based gel

Modern regenerative medicine is on the lookout for implantable materials that can change as the surrounding tissue does, and two Stanford University researchers have made some new gel materials that do just that. Karin Straley and Professor Sarah Heilshorn have developed a method for preparing protein-based implant materials that can evolve with the changing needs of the host biological system. Not only can their new materials change in different ways at different times, they can do so at different places within the implant materials.

31 Jul 2009

Three organizations form alliance to address global malnutrition

"Three internationally known organizations based in St. Louis - the Donald Danforth Plant Science Center, the Washington University School of Medicine and St. Louis Children's Hospital" - have entered into a partnership, known as the Global Harvest Alliance (GHA), which aims to "create inexpensive, nutritionally complete food to help the world's hungry and undernourished," the AP/Google.com reports.

29 Jul 2009

Nanodiamonds hold promise for wound-healing applications

Bacterial infection is a major health threat to patients with severe burns and other kinds of serious wounds such as traumatic bone fractures. Recent studies have identified an important new weapon for fighting infection and healing wounds: insulin.

27 Jul 2009